
    
      Patients with refractory pulmonary sarcoidosis will be eligible for participation in this
      open label trial of Rituximab as additional therapy. The study will evaluate the efficacy of
      rituximab in improving the symptoms and functional capacity in patients with chronic
      sarcoidosis with pulmonary involvement who are symptomatic despite current treatment.
    
  